Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy

Publisher： Karger

E-ISSN： 1423-0232|80|5-6|296-300

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.5-6, 2011-07, pp. : 296-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 219-225

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 190-195

Karger

Access to resources Recommend Favorite

Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 49-52

Karger

Access to resources Recommend Favorite

Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 91-100

John Wiley & Sons Inc

Access to resources Recommend Favorite